The New England journal of medicine|2025|Wharton S, Duque do Vale R, Garvey W|3 citations
PMID: 41370813
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
PURPOSE: Large telehealth companies and smaller aesthetic medicine providers used compounded semaglutide and tirzepatide to meet consumer demand for these drugs during their shortages. In this study, we estimate the documentation rate of compounded f…
Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with body weight, affecting more than 1 billion people worldwide. Excess body fat is strongly associated with excess energy i…
BACKGROUND: Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes are not established. METHODS: In this 26-week, double-blind trial, we randomly as…
PURPOSE: To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2025 in the United States, with a focus on the nonfederal hospital and clinic sec…
BACKGROUND: Limited access to specialist weight management services restricts the implementation of novel pharmacotherapies for obesity such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the UK National Health Service (NHS). Second Natur…
Cardiovascular disease mortality rates, which had steadily declined over decades, are now plateauing or reversing due to the global rise in type 2 diabetes mellitus (T2DM) and obesity. These cardiometabolic conditions contribute significantly to athe…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populatio…
Semaglutide, a glucagon-like peptide-1 receptor agonist, is known for weight reduction and glycemic control and is approved to lower major cardiovascular event risk in adults with overweight or obesity. While individual trials have explored its effec…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely accepted for managing Type 2 diabetes mellitus. However, numerous drug-related problems (DRPs) have recently been reported about GLP-1 RAs. OBJECTIVES: The present descripti…
GLP-1 receptor agonists (e.g., semaglutide) and dual GLP-1/GIP receptor agonists (e.g., tirzepatide) are effective for reducing body weight and fat mass, though lean soft tissue loss comprised 26%-40% of weight loss in recent trials. This case series…
Elucidating the neuronal circuits that govern appetite requires a detailed analysis of the microstructure of solid food consumption. A significant barrier in this field is that existing techniques for monitoring feeding are either prohibitively expen…
BACKGROUND: Semaglutide has emerged as an effective medication for treating type 2 diabetes mellitus (DM). However, the cardiovascular effects and safety of this agent in patients with heart failure with preserved ejection fraction (HFpEF) are unclea…
IMPORTANCE: Heart failure with preserved ejection fraction (HFpEF) is a major cause of hospitalization, often occurring in patients with cardiometabolic comorbidities such as obesity and type 2 diabetes. Although early trials of semaglutide and tirze…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes and obesity due to their metabolic effects. Emerging evidence suggests they may also have neuroprotective effects, indicating their potential as…
INTRODUCTION: Diabetes management involves using various oral hypoglycemic agents, including new glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide, tirzepatide, and liraglutide. Artificial intelligence (AI) tools such as ChatGPT (Ope…
INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists including Mounjaro and Ozempic, are increasingly used for weight management. Assessing the attitudes and beliefs of current and future healthcare professionals is important considering t…
BACKGROUND: There is a pressing requirement to formulate innovative approaches for addressing inadequate weight loss or recurrence in individuals following metabolic bariatric surgery (MBS). Glucagon-like peptide- 1 (GLP- 1) analogues such as liraglu…